BACKGROUND & AIMS This study aimed at developing a predictive algorithm based on interleukin 28B (IL28B) genotype, hepatitis C virus (HCV) genotype, and plasma HCV-RNA load, which could accurately allow us to define the probability of response to pegylated interferon (Peg-IFN) plus ribavirin (RBV) therapy in HIV/HCV-coinfected patients. METHODS Five hundred and twenty-one treatment-naive HIV-...

BACKGROUND/AIMS Polymorphism at the IL28B gene may modify the course of hepatitis C virus (HCV) chronic infection. Our aim was to study the influence of IL28B rs12979860 gene polymorphism on the biochemistry and pathology of HCV-induced disease in the clinical course from mild chronic hepatitis C to hepatocellular carcinoma. METHODS We have determined the rs12979860 single nucleotide polymorp...

The impact of hepatic steatosis on interferon therapy for patients with chronic hepatitis C (CHC) has been associated with single-nucleotide polymorphisms (SNP) of IL28B, patatin-like phospholipase domain-containing protein 3 (PNPLA3), and low-density lipoprotein (LDL) receptor. Whether this holds true for Japanese patients, however, remains unresolved. The present study prospectively enrolled ...

BACKGROUND Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR). OBJECTIVES To determine the role of IL28B genotype...

In the past 2 years the ability to successfully eradicate chronic HCV infection has been substantially enhanced by two landmark scientific breakthroughs. Firstly, the advent of HCV-specific direct-acting antiviral (DAA) compounds has resulted in a significant increase in sustained virological response rates in HCV genotype-1-infected treatment-naive patients and in non-responders to prior pegyl...

background: single nucleotide polymorphism in the interleukin28b (il28b) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis c. similarly, thyroid disease (td) occurring during treatment confer an improved sustained virologic response (svr). objectives: to determine the role of il28b genotype...

conclusions there were significant linkages between hcv genotypes and il28b genotypes/alleles. patients with a favorable il28b and genotypes 1 and 4 hcv infection stand a better chance to clear hcv in the acute phase. objectives this meta-analysis was designed to determine the world-wide distribution patterns of il28b genotypes and alleles, and to find possible linkages between il28b and hcv ge...

The qPCR and RFLP analyses disagreed in two cases (7.7%), where the rs8099917 genotype was determined by RFLP to be TT and qPCR indicated that it was TG. We arbitrarily considered the qPCR results to be the gold standard for analysis. The prevalence of IL28B CC (rs12979860) in European patients was 46% 7 and for TT (rs8099917) the prevalence was 51.5%, 9 whereas in the present study, the freque...

AIM To investigate the impact of IL28B and OAS gene polymorphisms on interferon treatment responses in children with chronic hepatitis B. METHODS We enrolled 52 children (between the ages of 4 and 18) with hepatitis B e antigen-negative chronic hepatitis B (CHB), who were treated with pegylated interferon alfa for 48 wk. Single nucleotide polymorphisms in the OAS1 (rs1131476), OAS2 (rs1293747...

Anti-hepatitis C virus (HCV) treatment in patients infected with human immunodeficiency virus (HIV) has become a focus of recent clinical investigations. HCV treatment efficacy appears to be dependent on the patient’s immunological status at the baseline, with the response rate being directly proportional to the pretreatment CD4 cell count [1, 2]. In HCV monoinfected individuals, a strong assoc...